as LC said over and over again, follow the science and the scientists, the money will follow them too. Just because IMU's B-cell vaxx haven't been sold yet means / meant they are duds / dusters. Instead of selling too early the vaxx and platforms will be taken up to regulators' approval and then partnered / sold.
As Hopper stated, patient capital is required but one thing is for sure, they already using the fast lane and are the safest in the business - remarkable. As much as some posters here complain about Hopper's companies management, his formula still works well for the scientists, sufferers and soon again for us holders too.
GLTA
IMU Price at posting:
13.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)